Free Access
Med Sci (Paris)
Volume 19, Number 8-9, Août-Septembre 2003
Page(s) 840 - 846
Section M/S Revues
Published online 15 August 2003
  1. Duh E, Aiello LP. Vascular endothelial growth factor and diabetes. The agonist versus antagonist paradox. Diabetes 1999; 48: 1899–906. [Google Scholar]
  2. The diabetes control and complication trial group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med 1999; 329: 977–87. [Google Scholar]
  3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulfonyureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53. [Google Scholar]
  4. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000; 321: 405–12. [Google Scholar]
  5. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813–20. [Google Scholar]
  6. Hammes HP, Du X, Edelstein D, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003; 9: 294–9. [Google Scholar]
  7. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunction in diabetic rats by an oral PKC β inhibitor. Science 1996; 272: 728–31. [Google Scholar]
  8. Munzel T, Keaney JF, Jr. Are ACE inhibitors a «magic bullet» against oxidative stress ? Circulation 2001; 104: 1571–4. [Google Scholar]
  9. Poulaki V, Qin W, Joussen AM, et al. Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor- 1alpha and VEGF. J Clin Invest 2002; 109: 805–15. [Google Scholar]
  10. Lorenzi M, Gerhardinger C. Early cellular and molecular changes induced by diabetes in the retina. Diabetologia 2001; 44: 791–804. [Google Scholar]
  11. Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, Adamis AP. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol 2001; 158: 147–52. [Google Scholar]
  12. Joussen AM, Poulaki V, Mitsiades N, et al. Suppression of Fas-FasLinduced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes. FASEB J 2003; 17: 76–8. [Google Scholar]
  13. Barber AJ. A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 283–90. [Google Scholar]
  14. Martin A, Komada MR, Sane DC. Abnormal angiogenesis in diabetes mellitus. Med Res Rev 2003; 23: 117–45. [Google Scholar]
  15. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249–57. [Google Scholar]
  16. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascularspecific growth factors and blood vessel formation. Nature 2000; 407: 242–8. [Google Scholar]
  17. Schaper W, Ito WD. Molecular mechanisms of coronary collateral vessel growth. Circ Res 1996; 79: 911–9. [Google Scholar]
  18. Semenza G. HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 2001; 107: 1–3. [Google Scholar]
  19. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964–7. [Google Scholar]
  20. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85: 221–8. [Google Scholar]
  21. Schatteman GC, Hanlon HD, Jiao C, Dodds SG, Christy BA. Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. J Clin Invest 2000; 106: 571–8. [Google Scholar]
  22. Tepper OM, Galiano RD, Capla JM, et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002; 106: 2781–6. [Google Scholar]
  23. Aiello LP, Wong JS. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int 2000; 77 (suppl): S113–9. [Google Scholar]
  24. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47: 859–66. [Google Scholar]
  25. Joussen AM, Poulaki V, Tsujikawa A, et al. Suppression of diabetic retinopathy with angiopoietin-1. Am J Pathol 2002; 160: 1683–93. [Google Scholar]
  26. Gilbert RE, Kelly DJ, Cox AJ, et al. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 2000; 43: 1360–7. [Google Scholar]
  27. Rivard A, Silver M, Chen D, et al. Rescue of diabetesrelated impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 1999; 154: 355–63. [Google Scholar]
  28. Lerman OZ, Galiano RD, Armour M, Levine JP, Gurtner GC. Cellular dysfunction in the diabetic fibroblast: impairment in migration, vascular endothelial growth factor production, and response to hypoxia. Am J Pathol 2003; 162: 303–12. [Google Scholar]
  29. Chou E, Suzuma I, Way KJ, et al. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulinresistant and diabetic states: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 2002; 105: 373–9. [Google Scholar]
  30. Lowe WL Jr, Florkiewicz RZ, Yorek MA, Spanheimer RG, Albrecht BN. Regulation of growth factor mRNA levels in the eyes of diabetic rats. Metabolism 1995; 44: 1038. [Google Scholar]
  31. Morishita R, Aoki M, Nakamura S, et al. Potential role of a novel vascular modulator, hepatocyte growth factor (HGF), in cardiovascular disease: characterization and regulation of local HGF system. J Atheroscler Thromb 1997; 4: 12–9. [Google Scholar]
  32. Spranger J, Osterhoff M, Reimann M, et al. Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes 2001; 50: 2641–5. [Google Scholar]
  33. Thurston G, Suri C, Smith K, et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999; 286: 2511–4. [Google Scholar]
  34. Portik-Dobos V, Anstadt MP, Hutchinson J, Bannan M, Ergul A. Evidence for a matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes. Diabetes 2002; 51: 3063–8. [Google Scholar]
  35. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389–95. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.